See where the industry is going before it gets there
Sleuth gives portfolio strategy teams a living competitive picture across pharma pipelines, modalities, and therapeutic areas. Peer benchmarking, signal detection, and portfolio-level analysis in one workspace.
The cost of misreading industry direction is measured in billions
Peer benchmarking doesn't scale
A real competitive read across twelve pharma pipelines, multiple therapeutic areas, and every development stage is a massive undertaking. The output is a snapshot, not a living picture.
Early signals hide in plain sight
An indication quietly getting crowded. A modality hitting scientific headwinds. A competitor building in an adjacent space. By the time your quarterly review catches it, it's consensus.
Portfolio questions, asset-level answers
Your decisions are about concentration risk, modality bets, and competitive positioning across the full pipeline. Your workflows are built for looking up individual drugs.
Built for how portfolio strategy teams actually work
The peer benchmarking is already done
Sleuth maintains continuously updated competitive views across pharma pipelines, therapeutic areas, and development stages. Your team spends its time on strategic interpretation, not data assembly.
Catch directional shifts before they're consensus
Sleuth monitors competitive landscapes continuously and flags the signals that matter to your strategic positioning. Your view updates as the landscape moves, not on a quarterly cycle.
Analysis built for the portfolio level
Sleuth operates across your full pipeline, not one drug at a time. Concentration risk, modality positioning, and competitive benchmarking at the altitude your decisions actually require.
What teams are saying
“What makes Sleuth stand out is that it is both fast and credible. The output is factual and structured enough that we can take it straight into internal discussions and executive conversations without having to double-check everything. It has fundamentally shifted our expectations for how quickly we can move from raw data to a high-conviction strategic narrative.”
